Rabeprazol Actavis Magasýruþolin tafla 10 mg Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

rabeprazol actavis magasýruþolin tafla 10 mg

actavis group ptc ehf. - rabeprazolum natríum - magasýruþolin tafla - 10 mg

Rabeprazol Actavis Magasýruþolin tafla 20 mg Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

rabeprazol actavis magasýruþolin tafla 20 mg

actavis group ptc ehf. - rabeprazolum natríum - magasýruþolin tafla - 20 mg

Evotaz Den europeiske union - islandsk - EMA (European Medicines Agency)

evotaz

bristol-myers squibb pharma eeig - cobicistat, atazanavir - hiv sýkingar - veirueyðandi lyf til almennrar notkunar - evotaz is indicated in combination with other antiretroviral medicinal products for the treatment of hiv-1 infected adults and adolescents (aged 12 years and older weighing at least 35 kg) without known mutations associated with resistance to atazanavir (see sections 4. 4 og 5.

Kaletra Den europeiske union - islandsk - EMA (European Medicines Agency)

kaletra

abbvie deutschland gmbh co. kg - lopinavir, rítónavír - hiv sýkingar - antivirals for systemic use, protease inhibitors - kaletra er ætlað ásamt öðrum antiretroviral lyf til meðferð hiv veira (hiv-1) sýkt fullorðnir, unglingum og börn á aldrinum 14 daga og eldri. val á kaletra að meðhöndla próteasahemla upplifað hiv-1 sýkt sjúklingar ætti að vera byggt á einstökum veiru mótstöðu próf og meðferð sögu af sjúklingum.

Vimpat Den europeiske union - islandsk - EMA (European Medicines Agency)

vimpat

ucb pharma sa - lacosamíð - flogaveiki - antiepileptics, - vimpat er ætlað sem einlyfjameðferð og viðbótarmeðferð við meðhöndlun á flogaveiki með eða án aukakvilla hjá fullorðnum, unglingum og börnum frá 4 ára með flogaveiki.

Lacosamide Accord Den europeiske union - islandsk - EMA (European Medicines Agency)

lacosamide accord

accord healthcare s.l.u. - lacosamíð - flogaveiki - antiepileptics, - lacosamide accord is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. lacosamide accord is indicated as adjunctive therapy•         in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. •         in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.